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Summary
Cysteine proteases mediate liberation of Plasmodium
berghei merozoites from infected hepatocytes. In
an attempt to identify the responsible parasite pro-
teases, we screened the genome of P. berghei for
cysteine protease-encoding genes. RT-PCR analyses
revealed that transcription of four out of ﬁve
P. berghei serine repeat antigen (PbSERA) genes was
strongly upregulated in late liver stages brieﬂy before
the parasitophorous vacuole membrane ruptured
to release merozoites into the host cell cytoplasm,
suggesting a role of PbSERA proteases in these
processes. In order to characterize PbSERA3 pro-
cessing, we raised an antiserum against a non-
conserved region of the protein and generated a
transgenic P. berghei strain expressing a TAP-tagged
PbSERA3 under the control of the endogenous
promoter. Immunoﬂuorescence assays revealed that
PbSERA3 leaks into the host cell cytoplasm during
merozoite development, where it might contribute to
host cell death or activate host cell proteases that
execute cell death. Importantly, processed PbSERA3
has been detected by Western blot analysis in cell
extracts of schizont-infected cells and merozoite-
infected detached hepatic cells.
Introduction
Despite 100 years of malaria research, malaria remains
one of the world most deadly diseases, causing more than
one million deaths per year. The causative agent of
malaria, the Plasmodium parasite, is transmitted by the
bite of an infected Anopheles mosquito. Research on the
rodent malaria parasite P. berghei revealed that transmit-
ted sporozoites are deposited under the skin from where
they enter blood vessels to eventually reach the liver with
the blood stream (Amino et al., 2005). By traversing
Kupffer cells (Baer et al., 2007a), sporozoites gain access
to the liver tissue where they transmigrate through a
number of hepatocytes (Mota et al., 2001), before ﬁnally
invading one by formation of a parasitophorous vacuole
(PV). Inside this vacuole, the parasite develops into a
large, multinucleated body called the liver schizont. The
liver schizont differentiates into several thousand merozoi-
tes that must enter blood vessels to infect red blood cells
(RBCs). During this process, the host cell undergoes a
number of dramatic morphological changes, observed as
detachment from the neighbouring cells and eventually
formation of merosomes (Sturm et al., 2006; Sturm and
Heussler, 2007). Merosomes are merozoite-ﬁlled, host
cell-derived vesicles that migrate into the adjacent blood
vessel of the liver tissue and therefore seem to function as
asafetransportsystemthatdeliversparasites,undetected
by the immune system, into the blood stream. In vitro,
P. berghei-infected HepG2 cells detach at the end of the
exoerythrocytic stage and ﬂoat into the culture media,
wheretheyalsoformmerosomes(Sturmet al.,2006).This
entire process can be inhibited by treating infected cells
with the general cysteine protease inhibitor E64. Previ-
ously, it has also been shown that E64 blocks merozoite
release from infected RBCs (Salmon et al., 2001;
Wickhamet al.,2003),suggestingacrucialroleofcysteine
protease during parasite liberation. P. falciparum SERA
proteins are a family of nine conserved putative cysteine
proteases thought to play a key role in liberation of blood
stage parasites from RBCs and sporozoites from oocysts
(Hodder et al., 2003; Bourgon et al., 2004; Arisue et al.,
2007). Each examined Plasmodium species possesses
SERAs of two major groups, speciﬁed as ‘cysteine-type
SERAs’ and ‘serine-type SERAs’. Serine-type SERAs
contain an active site serine residue instead of the canoni-
cal cysteine residue (Hodder et al., 2003; Bourgon et al.,
2004). P. falciparum SERA5 (PfSERA5), also known as
SERP and p126 (Delplace et al., 1987; Bzik et al., 1988;
Knapp et al., 1989), is the best-characterized SERA pro-
tease. In a series of elegant studies it has been shown that
p126 or SERA5 becomes proteolytically processed in
several steps to ﬁnal peptide of 50 kDa (Delplace et al.,
1985; 1987; 1988; Debrabant and Delplace, 1989;
Debrabant et al., 1992). Leupeptin-dependent inhibition of
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50 kDa peptide still allowed the release of blood stage
merozoites from the PVM but blocked the liberaton of
merozoitesfromtheinfectedcell(DebrabantandDelplace,
1989), which is a striking similarity to the inhibition of
merozoite release in E64-treated infected hepatocytes
(Sturm et al., 2006).
As the genomes of different Plasmodium species
contain different numbers of SERA genes (Arisue et al.,
2007; McCoubrie et al., 2007), there is some confusion
about the nomenclature of the SERA family. We decided
to adopt the names recently suggested (Arisue et al.,
2007), although they do not match the results of homology
and synteny searches (McCoubrie et al., 2007). For
example, P. falciparum SERA3 is a serine-type SERA,
whereas P. berghei SERA3 is a cysteine-type SERA.
It has been shown that immune responses against
the N-terminal part of PfSERA5 correlate with immunity
against malaria (Okech et al., 2001; Okech et al., 2006)
and thus SERAproteases might be interesting candidates
for vaccine design. Here, we describe the expression and
localization of P. berghei cysteine-type SERA3 during late
liver stages of the parasite and provide evidence for its
processing.
Results
Cysteine proteases are involved in merozoite release
from the PV in P. berghei-infected HepG2 cells
It has been shown for both, Plasmodium blood stages
(Salmon et al., 2001; Li et al., 2002; Wickham et al., 2003)
and Plasmodium liver stages (Sturm et al., 2006) that
cysteine protease inhibitors can block the process of
merozoite release. The liberation of exoerythrocytic
P. berghei merozoites from the PV was effectively blocked
by the irreversible cysteine protease inhibitor E64. To
further characterize protease function during this process,
we treated P. berghei-infected HepG2 cells 48 h post
infection with 100 mmm l -1 leupeptin and antipain, two
serine and cysteine protease inhibitors (Fig. 1A) and
counted the detached cells 67 h after infection. Both
inhibitors blocked cell detachment considerably but not
completely compared with untreated cells. Infected cells
that still detached despite inhibitor treatment exhibited a
different phenotype depending on the drug used (inserted
images in Fig. 1A). In leupeptin-treated cultures, merozoi-
tes in detached cells were still surrounded by a PVM
within the host cell. On the other hand, detached cells in
antipain-treated cultures looked similar to detached cells
Fig. 1. A. Cysteine and serine protease
inhibitors block detachment of
P. berghei-infected HepG2 cells. HepG2 cells
were infected with P. berghei sporozoites.
Upon cultivation for 48 h, cells were treated
with 100 mM of either antipain or leupeptin for
an additional 13 h. Detached cells in treated
and untreated control wells were counted and
expressed as a percentage of control
(untreated) cells. Error bars have been
calculated from data of three independent
experiments.
B. The SERA gene family of P. berghei
consists of ﬁve members, aligned in a tandem
cluster. Dark grey boxes represent exons of
the ‘cysteine-type’ SERA members, light grey
boxes symbolize the exons of ‘serine-type’
SERAs.
C. PbSERA1–4 expression is upregulated in
late liver stages. HepG2 cells were infected
with P. berghei sporozoites and mRNA of
these infected cells was prepared at 24, 38,
50 and 62 h post infection. Messenger RNA
expression of all ﬁve PbSERAs was veriﬁed
by RT-PCR. As a control, tubulin mRNA was
additionally ampliﬁed.
D. PbSERA mRNA expression is stage
speciﬁcally regulated. mRNA expression of all
ﬁve PbSERAs was veriﬁed by RT-PCR. Total
mRNA was isolated from two mosquito stages
(oocysts and salivary gland sporozoites), and
from three parasite stages of the vertebrate
host (late liver schizont stage, detached
cells/merosomes and the blood stages) and
subjected to RT-PCR analysis.
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freely with the host cell cytoplasm. These results suggest
that the inhibitors either act on different proteases or
inhibit the same protease by different mechanisms. It has
indeed been shown that leupeptin and antipain have dif-
ferent inhibitory effects on deﬁned proteases (Otto and
Schirmeister, 1997). The fact that leupeptin treatment pre-
served the PVM structure in infected detached cells
whereas in antipain-treated detached cells merozoites
were liberated from the PV supports the hypothesis that
more than one protease is involved in parasite liberation
and induction of host cell death. One likely scenario is that
a kind of ‘initiator’ protease induces the processing of
‘effector’ proteases and their activation results in the
observed phenotype. Depending on which stage the
individual inhibitors act, destruction of the PVM, cell
detachment or host cell death might be affected.
Transcription of four SERA genes is strongly
upregulated in late liver stages
We reasoned that proteases that are responsible for PVM
destruction and merozoite liberation into the host cell
cytoplasm are most likely of parasite origin and thus, we
performed database searches for Plasmodium cysteine
proteases containing a signal sequence. To focus on
candidate proteases relevant for merozoite liberation, a
second selection criterion was the proof of an upregulated
transcription towards the end of the liver stage, brieﬂy
before PVM damage. Reverse transcription polymerase
chain reaction (RT-PCR) analysis revealed a strongly
enhanced expression of ﬁve cysteine protease mRNAs in
late liver stages, including a putative cysteine protease
annotated as PB000888.02.0 (data not shown) and four
PbSERA proteases (Fig. 1C). Unlike P. falciparum, which
possesses nine SERA protease genes (Miller et al.,
2002), the P. berghei genome contains only ﬁve (Fig. 1B
and Fig. S1) (Bourgon et al., 2004; Arisue et al., 2007),
with PbSERA1–4 but not PbSERA5 expressed in late liver
stages. Importantly, mRNA expression of PbSERA1–4
could hardly be detected during the ﬁrst 38 h post infec-
tion, whereas expression was strongly upregulated 50 h
post infection (Fig. 1C). Further characterization of the
SERA3 promoter largely conﬁrmed the RT-PCR results.
We cloned the complete 5′ UTR of SERA3 in front of GFP
within a P. berghei transfection plasmid. Transfected
P. berghei parasites do not express GFP in early liver
stages but show a strong GFP expression towards the
end of the exoerythrocytic stage, in particular during
merozoite formation (Fig. S2).
Similarly to other SERA protease genes that have been
identiﬁed (Arisue et al., 2007; McCoubrie et al., 2007),
PbSERAgenes are arranged in a tandem cluster (Fig. 1B)
that contains two serine-type SERAs (PbSERA1, -2) and
three cysteine-type SERAs (PbSERA3, -4 and -5). Align-
ment of the amino acid sequences of the ﬁve PbSERAs
and PfSERA5 of P. falciparum revealed highly conserved
areas including the protease-like domain in the central
region and areas of low homology at the N- and C-termini
of the proteins (Fig. S1). RT-PCR analysis was used to
determine stage-speciﬁc mRNA expression of SERA
genes throughout the life cycle of the parasite. Messenger
RNA was isolated from two mosquito stages (oocysts
and salivary gland sporozoites) and three
mammalian stages (late liver schizonts, detached cells/
merosomes, infected erythrocytes) and subjected to
RT-PCR using primers speciﬁc for each PbSERA cDNA
(Fig. 1D). Whereas PbSERA1 mRNA expression was
detected in oocysts, late liver stage parasites, detached
cells/merosomes and infected RBCs, PbSERA2–4 gene
transcription was restricted to mammalian stages. On the
other hand, PbSERA5 mRNA could only be detected in
mosquito stages, conﬁrming previous results (Aly and
Matuschewski, 2005).
PbSERA3 is processed in late liver stages
To produce an antiserum that speciﬁcally recognizes
PbSERA3, rats were immunized with the variable
N-terminal region of the protein. It is well established that
SERAproteases of P. falciparum undergo several steps of
processing but nothing was known about processing
of the P. berghei homologues. To investigate processing
of PbSERA3 during blood and liver stages, we performed
Western blot analysis using the anti-PbSERA3-N antise-
rum (Fig. 2). Several PbSERA3 protein fragments were
detected in cell extracts of blood stage parasites, infected
HepG2 cells and also in detached cells and merosomes.
Whereas in extracts of blood stage parasites, full-length
PbSERA3 (130 kDa) and processed forms of 72 and
55 kDa were recognized by the antiserum, a processed
55 kDa PbSERA3 was the main fragment in late infected
HepG2 cells and in detached cells/merosomes detected
by the antiserum used for this experiment. The 55 kDa
species most likely corresponds to the N-terminal frag-
ment P47, which is the result of SERA5 processing in
P. falciparum blood stage parasites (Li et al., 2002) and
does not correspond to the mature PbSERA3 protease.
Saponin treatment, which releases the content of the PV,
suggested that in blood stage parasites, PbSERA3 is ﬁrst
secreted into the PV and subsequently processed, most
likely by other proteases in the PV (Fig. 2).
TAP-tagging of PbSERA3
To further characterize processing of PbSERA3 in adher-
ent infected HepG2 cells, we used single cell analysis
using IFA techniques. The aim was to use antibodies
against both ends of the protein for staining of different
PbSERA3 processing during liver stages 1725
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two antibodies would represent detection of the full-length
protein whereas different staining patterns would indicate
processing. To detect the N-terminus we used the antise-
rum described above and for detection of the C-terminus,
we generated a transgenic parasite strain, expressing
full-length PbSERA3 fused to a TAP-tag at the C-terminus
(Fig. 3A). Southern blot analysis was used to conﬁrm the
integration of the tagged PbSERA3 DNA sequence into
the correct gene locus (Fig. 3B). Expression of this addi-
tional tagged SERA protease had no effect on parasite
development throughout the life cycle (Fig. S3).
Protein extracts of puriﬁed wild-type (WT) P. berghei
blood stage parasites and transgenic parasites express-
ing additionally to the endogenous PbSERA3, TAP-
tagged PbSERA3, were ﬁrst analysed by Western blotting
to demonstrate a normal processing of the tagged protein.
Puriﬁed WT or transgenic parasites were treated with
saponin to initially extract proteins present in PV (Fig. 4B).
A subsequent lysis with NP40 was used to extract soluble
proteins from the parasite. As shown in a schematic illus-
tration in Fig. 4A, human IgG is expected to detect TAP-
tagged full-length and processed C-terminal fragments of
PbSERA3-TAP, but no reactivity is expected for the
endogenous PbSERA3. On the other hand, the anti-
PbSERA3-N antiserum should recognize both full-length
proteins and the N-termini of the processed forms of
PbSERA3 as well as TAP-tagged PbSERA3. For both WT
and transgenic parasite preparations, full-length proteins
were primarily found in the PV (saponin extraction)
whereas processed forms were mainly detected in para-
site extracts (Fig. 4B) conﬁrming the results presented in
Fig. 2. As these fragments are present in WT and trans-
genic parasite and because they are also not detected by
the anti-TAP human IgG, it can be concluded that they
lack the C-terminus of the protein. Importantly, during
the blood stage of the parasite TAP-tagged PbSERA3
appeared to be processed similarly to WT PbSERA3 with
the exception of a processed form of about 50 kDa, which
was not present in extracts of WT parasites. The four main
protein fragments detected in saponin- and NP40-extracts
of transgenic parasites by human IgG correspond to four
Fig. 2. Processing of PbSERA3 in liver and blood stages.
Saponin and NP40 extracts of erythrocytic stage (ES) were
made and compared with whole-cell SDS lysates of detached
cells/merosomes (dc/m), FACS-sorted HepG2 cells containing 50 h
exoerythrocytic schizonts (EE) cells and non-infected HepG2 cell
lysates (co) by Western blot analysis using an anti-PbSERA3-N
antiserum.
Fig. 3. Integration of a TAP-tagged copy of
PbSERA3 into the SERA locus. Shown are
schematic representations detailing the
outcome of the expected integration event.
A. Wild-type PbSERA locus showing part of
the PbSERA2 gene (white box) and the
PbSERA3 gene (grey box) with 5′ UTR and 3′
UTR (upper part). The pL0032-PbSERA3
targeting construct including the 5′ UTR and
full-length PbSERA3 gene (without STOP
codon) fused to a TAP-tag (black box), the 3′
pbdhfr/ts sequence and a selectable tgdhfr/ts
marker cassette (middle part) was integrated
into the PbSERA3 locus (lower part). F = FnuI
restriction sites. The expected fragments are
indicated.
B. Southern blot analysis showing the correct
integration event. Wild-type parasites and
transfected parasites were isolated from
infected mice and genomic DNA was
prepared. Upon FnuI digestion, Southern
blot analysis was performed using a
PbSERA3-speciﬁc DNA probe. The location of
the probe is indicated in (A).
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tag as illustrated in Fig. 4A. The simultaneous occurrence
of many PbSERA3 peptides in Western blot experiments
in comparison to relatively limited number of fragments
in Western blot analysis of P. falciparum cell extracts
(Li et al., 2002) reﬂects most likely the non-synchronous
growth of P. berghei in mice. To conﬁrm this assumption,
we synchronized P. berghei blood stage parasites
(WT parasites and PbSERA3-TAP expressing parasites)
in vitro and repeated the Western blot analysis with
lysates of highly enriched schizonts (Fig. S4). As
expected, processing was more pronounced when com-
pared with lysates of mixed cultures. The prominent
72 kDa protein detected in mixed cultures by the antise-
rum directed against the N-terminus is not present in
lysates of synchronized cultures (Fig. S4A). However,
when the blot was probed with anti-TAP antiserum (Fig.
S4B), no difference was seen to the experiment with
mixed culture lysates, suggesting that N-terminal but not
C-terminal processing occurs in blood stage schizonts.
Subcellular localization of PbSERA3
Western blot analysis of blood stage parasite extracts
suggested that processed PbSERA3 forms exists in the
PV and in the parasite. To determine the subcellular local-
ization of PbSERA3 in late liver stage parasites, indirect
immunoﬂuorescence analysis was performed. To prove
whether the TAP-tagged and the endogenous versions
of PbSERA3 colocalize, we stained schizont-infected
HepG2 cells with both human IgG to detect TAP-tagged
PbSERA3 and with the antiserum directed against the
N-terminus of PbSERA3 (Fig. 5A). The vast majority of
the detected proteins indeed colocalized in deﬁned
regions of the parasite, indicating that the TAP-tag does
not alter the localization of the tagged protein. Using the
PbSERA3-N antiserum a similar staining pattern was also
seen in HepG2 cells infected with WT parasites (Fig. S5),
conﬁrming that additional expression of TAP-tagged
PbSERA3 has no effect on the localization of the protein.
From this experiment, it can be concluded that human IgG
is indeed suitable for detection of the TAP-tagged
C-terminus of PbSERA3 at the correct location. Impor-
tantly, in ﬁxed liver sections of P. berghei-infected mice,
the staining pattern obtained by anti-PbSERA3-N antise-
rum detection resembled the in vitro acquired results with
PbSERA3-N localizing mainly in the parasite cytoplasm
and close to the PVM (Fig. 5B and C).
In order to inhibit SERA processing, we treated infected
HepG2 cultures 48 hpi with E64 and stained the cells with
anti-TAP and anti-PbSERA3-N 56 hpi. Additionally, the
PVM was visualized using an anti-Exp1 antiserum. At this
time point, in a substantial number of infected non-treated
control cells, PbSERA3 was found in the host cell cyto-
plasm whereas in E64-treated cells, PbSERA3 was
restricted to the parasite. In Fig. 6, representative images
Fig. 4. Western blot analysis of wild-type
PbSERA and PbSERA3-TAP-expressing
P. berghei blood stage protein extracts.
A. Schematic representation of endogenous
PbSERA3 protein and TAP-tagged PbSERA3.
The epitopes against which the different
antibodies are directed (anti-PbSERA3-N and
anti-TAP) are indicated.
B and C. Wild-type (WT) or transgenic
parasites (TAP) were initially lysed with
saponin to extract proteins present in the PV
and subsequently treated with NP40 to extract
soluble parasite proteins. Western blot
analysis was performed using antibodies
directed against the PbSERA3 N-terminus (B)
or the TAP-Tag (C). Molecular weight markers
(in kDa) are shown on the left side of each
blot. The arrows indicate the full-length
TAP-tagged PbSERA3 and the asterisk in C
labels an unspeciﬁc band.
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PVM ruptures, releasing PbSERA3-N and C into the host
cell cytoplasm (Fig. 6A). However, a closer examination of
thestainingpatternsrevealedsomeinterestingdifferences
in the distribution of PbSER3-N and C fragments.
PbSERA3-N was found equally distributed over the
remaining parasite structure and the host cell but was
absent from the host cell nucleus. In contrast, the
Fig. 5. PbSERA3 localization in
P. berghei-infected HepG2 cells and in
hepatocytes. Infected HepG2 cells were ﬁxed
48–60 h post infection and stained with
anti-TAP (red), anti-PbSERA3-N (green),
anti-ExpI (cyan) to visualize the PVM and the
DNA dye DAPI (blue). (A) Schizont stage;
(B) cytomere and merozoite stage; (C) section
of a P. berghei-infected liver stained with
anti-PbSERA3-N (red), anti-ExpI (green) and
DAPI (blue). Bar = 10 mM.
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concentrated to the parasite. Staining of the host cell
cytoplasm with anti-TAP was less pronounced than was
seen for anti-PbSERA3-N staining. Despite the reduced
occurrence of PbSERA3-C in the host cell, it was found in
the nucleus of the host cell.Together, the differences in the
staining pattern clearly conﬁrm PbSERA3 processing at
this stage in non-treated control cells. On the other hand,
the PVM in E64-treated cells appeared to be intact and in
the vast majority of infected cells, no PbSERA3 transloca-
tion to the host cell cytoplasm was observed (Fig. 6B).
Importantly, PbSERA3-N and PbSERA3-TAP colocalized
almost completly, indicating that PbSERA3 is indeed inhib-
ited by E64 treatment.
With the transgenic parasite line expressing a TAP-
tagged PbSERA3 we now have a valuable tool to perform
colocalization experiments with other PbSERAs. Together
with a panel of speciﬁc antibodies, this should help us to
analyse PbSERA expression, localization and processing
during the liver stage of the parasite in detail. Figure 7
provides the ﬁrst hint that PbSERA localization might vary
considerably during the exoerythrocytic parasite stage.
Quadruple labelling experiments using human IgG,
mouse anti-PbSERA1, chicken anti-Exp1 and DAPI were
Fig. 6. Inhibition of cysteine protease activity
by E64 inhibits PbSERA3 release in the host
cell cytoplasm. A total of 48 hpi infected
HepG2 cells were treated with E64 (B) or
were left untreated as a control (A) and
cultured for additional 15 h. Cells were ﬁxed
and stained as described above. The asterisk
in (A) labels the host cell nucleus, which
contains already the TAP-tagged C-terminus
of PbSERA3 but not its N-terminus.
Arrowheads mark the parasite dimensions in
the infected cell. The arrow indicates an area
of high PbSERA3-N concentration. Note that
the concentration of TAP-tagged C-terminus is
clearly lower (red staining). Bar = 10 mM.
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stages. In cytomere-stage parasites, PbSERA3 localized
mainly in the parasite cytoplasm and the PVM, with little
protein located in the PV (Fig. 7, upper panel). Interest-
ingly, at this stage, PbSERA1 was predominantly detected
in the PV, suggesting a different localization of both
PbSERA proteins. When merozoites have been formed,
both antibodies label the already damaged PVM and the
host cell cytoplasm (Fig. 7, middle panel). Finally, in
detached cells, the PVM is completely disintegrated and
PbSERA-1 and -3 are found in the host cell in distinct foci,
which do not completely overlap (Fig. 7, lower panel). It
should be noted that in cell extracts of detached cells/
merosomes, only processed PbSERA3 protein was
detected by Western blotting (Fig. 2), suggesting that TAP
detection at this stage visualizes the processed
C-terminus of the protein.
Discussion
Here, we present for the ﬁrst time evidence that four
putative proteases of the PbSERAfamily are expressed in
late liver stages and that PbSERA3 becomes processed
during merozoite development. In the activated state,
PbSERA3 might contribute to the observed PVM destruc-
tion and merozoite liberation as has been postulated for
SERA5 during the blood stage of P. falciparum (Hodder
et al., 2003). Although there is no doubt that cysteine
proteases mediate PVM destruction and facilitate mero-
zoite release from hepatocytes, additional factors might
be required to guarantee release of merozoites from
merosomes. It has recently been shown that merosomes
migrate out of the liver and reach the lung (Baer et al.,
2007b). It might well be that in the microvasculature,
a pressure-driven merozoite release occurs similarly to
Fig. 7. PbSERA3-C and PbSERA1-M localization in infected HepG2 cells. P. berghei-infected HepG2 cells were ﬁxed at different time points
post infection and stained with anti-TAP (red), anti-PbSERA1-M mAb (green), anti-Exp1 (cyan) and DAPI (blue). Arrows indicate SERA
localization in the host cell cytoplasm. For easier interpretation, only images obtained with anti-TAP and anti-PbSERA1 were merged.
Yellow colour indicates colocalization. Bar = 10 mM.
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release from erythrocytes (Glushakova et al., 2005). Our
own in vitro live imaging of P. berghei-infected hepato-
cytes supports this view. We observed that merozoites are
not all released at once from merosomes but are liberated
in several convulsive eruptions over a period of about 1 h.
After the release of 10–20 merozoites the merosome
membrane is closed again until the next eruption (V.T.
Heussler, unpubl. obs.). This form of merozoite release
might well be triggered by increased osmotic pressure,
which decreases upon merozoite release and again
increases once the membrane is re-sealed. However, the
fact that the entire process of PVM degradation and mero-
zoite liberation can be blocked by different protease
inhibitors demonstrates clearly that proteases appear to
act as initiators of merozoite release.
We found that mRNA expression of four PbSERA pro-
teases was strongly upregulated brieﬂy before merozoite
development. Furthermore, we could show by IFA that,
at this stage, PbSERA1 translocated predominantly into
the PV. Upon disruption of the PVM, PbSERA1 and
PbSERA3-C were localized in the host cell cytoplasm,
suggesting a role in the subsequent host cell death. SERA
proteases have also been proposed to mediate parasite
liberation from P. falciparum-infected erythrocytes with
PfSERA5 being processed brieﬂy before merozoite libera-
tion (Hodder et al., 2003) and it appears likely that the
molecular mechanisms of Plasmodium merozoite libera-
tion from infected erythrocytes and hepatocytes are
similar. It has already been shown that P. falciparum
SERA5 has a weak proteolytic activity (Hodder et al.,
2003), but the physiological roles of the different SERAs
and their substrates in infected cells are still not known
(McCoubrie et al., 2007). Approaches to knockout the dif-
ferent P. falciparum SERAs expressed during the blood
stage either did not generate an apparent phenotype or
were lethal (Miller et al., 2002; McCoubrie et al., 2007).
Obviously, knockout of some PfSERAs can be compen-
sated by upregulating the expression of others (McCou-
brie et al., 2007) and thus alternative approaches like
inducible expression or stage-speciﬁc expression (Car-
valho et al., 2004) have to be considered in the future to
determine the function of the individual SERAs in blood
and liver stages. As we show here that PbSERA pro-
teases localize to different compartments in infected
hepatocytes, it is also possible that not only expression
levels but also the change in protein localization might
compensate for the lack of certain SERAs in knockout
parasites. Staining of large liver stage parasites is much
easier to perform and to interpret than staining of infected
RBCs and thus P. berghei-infected hepatocytes might turn
out to be a valuable tool to analyse the localization and
the function of SERA proteases in general. The most
important evidence that SERA proteases are involved in
parasite liberation comes indeed from knockout studies
performed in P. berghei (Aly and Matuschewski, 2005).
These authors had demonstrated that PbSERA5 expres-
sion is restricted to the insect stage and thus selection of
knockout parasite strains during the blood stage was
possible. Parasites lacking functional PbSERA5 did not
show defects in mosquito infection or in the development
of sporozoites within oocysts. However, PbSERA5-
knockout sporozoites were not able to leave mature
oocysts and no salivary gland infection was observed.
Another intriguing question is why Plasmodium parasites
express several rather similar proteases at the same time.
Our observation that the localization of these proteases
differs considerably within infected cells provides an
explanation for this simultaneous expression. Alterna-
tively, the different SERA proteases might be arranged in
cascades with one SERA processing another member of
the family similarly to what is known for caspases in
metazoans. As we expect that mature PbSERA pro-
teases, once translocated to the cytoplasm of the infected
hepatocyte, are responsible for executing host cell death,
this would indeed be a striking analogy with initiator
caspases and executor caspases triggering apoptosis in
other organisms. Interestingly, the genome of Theileria
annulata, which is a closely related parasite to Plasmo-
dium, contains also a SERA gene (McCoubrie et al.,
2007). As Theileria parasites actively inhibit host cell apo-
ptosis during the schizont stage but kill their host cell
during merozoite release (Heussler et al., 2002), it will be
highly interesting to determine the expression and the
function of the putative protease during parasite liberation
from infected leukocytes. For Plasmodium-SERAs, the
next challenge is to decipher their function in detail, in
particular to deﬁne their role in the execution of host
cell death. The work presented here provides a good
basis for further analysis of SERA function, and some
exciting ﬁndings can be expected in the near future.
Experimental procedures
Experimental animals
Animals were from Charles River Laboratories. All animal work
was conducted in accordance with European regulations and
approved by local state authorities.
PbSERA gene prediction and amino acid
sequence alignment
Homology searches for P. berghei sequences similar to
PySERA1–5 and the annotated PfSERA1–9 genes were per-
formed with the basic local alignment search tool (BLAST)
program of the GeneDB website or of PlasmoDB website. cDNA
sequences were translated and then aligned using the CLUSTAL
W programme of MacVector.
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For RT-PCR analysis, total RNA was isolated from 6 ¥ 105 WT
salivary gland sporozoites, 10
6 WT oocyst sporozoites, infected
HepG2 cells at different time points post infection, detached
cells/merosomes or from 0.15% saponin-treated (Sigma) blood
stage parasites (RBC stage) using the RNA Extract Kit II
(Machery and Nagel). First strand cDNA was synthesized with
the Superscript
TM First-Strand Synthesis System for RT-PCR
(Invitrogen) using 200 ng of each total RNA. Target cDNAs were
ampliﬁed using the following primer sets: PbSERA1/for (5′-
TTAGATGCAGCCGACACAAG-3′) and PbSERA1/rev (5′-TACT
CCATTTCGCAGCACAA-3′); PbSERA2/for (5′-TTCCCTTTCAC
CACAACCTC-3′) and PbSERA2/rev (5′-TCACATTTGTTCGT
TTCTGGA-3′); PbSERA3/for (5′-ATGGCACGTCTCTCATCAAT-
3′) and PbSERA3/rev (5′-TGTGGTGAAAATTGAACTCTGAA-3′);
PbSERA4/for (5′-CACGAAATTAATACGCAAACCT-3′) and
PbSERA4/rev (5′-TCATTAGTGTGTGTTTCCCATT); PbSERA5/
for (5′-TCTGGAACAAGCAATTTACAAAAA-3′) and PbSERA5/
rev (5′-TCAGCGAATCCAAGTCCTTT-3′). As an internal control,
a primer set (Pbtubulin/for (5′-TGGAGCAGGAAATAACTGGG-
3′) and Pbtubulin/rev (5′-ACCTGACATAGCGGCTGAAA-3′) that
annealed to P. berghei tubulin was used. All RNA preparations
were free of genomic DNA (gDNA) contamination as no PCR
product was obtained when reverse transcriptase has been
omitted from the RT-PCR (negative control).
In vitro infection of HepG2 cells
Human hepatoma cells (HepG2) were obtained from the Euro-
pean cell culture collection. Cells were cultivated at 37°C and
5% CO2 in EMEM (Gibco), containing 10% fetal calf serum, 1%
L-glutamine, 1% penicillin/streptomycin and 1% MEM non-
essential amino acids (all PAA Laboratories GmbH, Pasching,
Austria). The cells were passaged by trypsinization every
4–6 days and for infection, 10
5 cells were seeded per coverslip in
a 24-well plate. P. berghei WT (ANKA) or transgenic sporozoites
were prepared from dissected salivary glands of infected Anoph-
eles stephensi mosquitoes and incubated with HepG2 cells for
2 h. After washing, the infected cultures were incubated at 37°C
until the indicated times.
SDS-PAGE and Western blotting
Parasite proteins obtained from 55% Nycodenz-enriched blood
stage schizont preparation or collected ﬂoating cells/merosomes
were separated on 12% SDS-PAGE reducing gels and trans-
ferred to nitrocellulose membranes. Membranes were probed
with rat antisera directed against the N-terminus of PbSERA3
(PbSERA3-N) or human gamma-globulins (anti-TAP, Sigma).
Horseradish peroxidase-conjugated goat anti-rat or anti-human
IgG (Pierce) were used for detection, and bands were visualized
using enhanced chemiluminescence Pico Detection Kit (Pierce).
Immunoﬂuorescence microscopy
For analysis of SERA localization in late liver stages, infected
HepG2 cells were ﬁxed with 4% formaldehyde, permeabilized
with ice-cold methanol and incubated with primary antibodies
(1:400 in 10% FCS diluted in PBS) or human gamma-globulin
(10 mgm l -1 in 10% FCS diluted in PBS). Bound antibodies were
detected using anti-human Alexa Fluor 594-, anti-rat Alexa Fluor
488- or anti-chicken Cy5-conjugated secondary antibody
(Molecular Probes, Leiden, the Netherlands). To identify the PVM
of intracellular parasites, cells were stained with a parasite-
speciﬁc chicken anti-PbExp1 antibody. Nuclei of the cells were
visualized with a 10 mgm l
-1 aqueous solution of DAPI (Sigma-
Aldrich, Germany). Immunoﬂuorescence-labelled cells were
examined by confocal microscopy using the Olympus FV1000
(SIM-scanner and spectral detection).
Immunohistological staining
For analysis of PbSERA3 localization in vivo, female C57BL/6
mice were infected intravenously with 2.5 ¥ 10
5 P. berghei WT
(ANKA) sporozoites. Forty-eight hours post infection, mouse liver
samples were ﬁxed in HOPE Solution I (Hepes Glutamic Acid
buffer mediated organic Solvent Protection effect; DCS,
Hamburg) and were embedded in paraffin. Sections of 2 mm were
treated with 0.5% Triton X-100 diluted in PBS and stained with rat
anti-PbSERA3-N and chicken anti-Exp1 antibodies, diluted to
1:100, followed by detection with anti-rat-Alexa 594 and
antichicken-Cy2. DAPI was used to stain the nuclei of the host
cell and the parasite.
Antibodies
Expression and puriﬁcation of recombinant GST fusion proteins.
RT-PCR was used to clone PbSERA1, and PbSERA3 cDNA.
BamHI/EcoRI sites and XhoI sites were introduced at the end of
forward and reverse primers respectively (restriction enzyme
sites are underlined): SERA3/for (5′-GTGGATCCATGGCACGT
CTCTCATCAAT-3′) and SERA3/rev (5′-GTCTCGAGATGTGGT
GAAAATTGAACTCTGAA-3′); SERA1/for (5′-GTGTGAATTCTTA
GATGCAGCCGACACAAG-3′) and SERA1/rev (5′-GACTCGAG
TTATCCTTCTCCAGTTGGTTGATG-3′). The resulting PCR
products were ligated into the appropriate pGEX vectors and
expressed in Escherichia coli BL21 cells (Stratagene) as glu-
tathione S-transferase (GST) fusion proteins. GST fusion pro-
teins of PbSERA1 (Leu
877-Gly910) or PbSERA3 (Met1-Phe235)
were harvested by suspending bacteria expressing SERA pro-
teins in 10 ml buffer A (10 mM EDTA in PBS) in the presence of
Complete™ Protease Inhibitor mixture tablets (Roche Molecular
Biochemicals) for 30 min followed by soniﬁcation. The recombi-
nant SERA fusion proteins were puriﬁed from the supernatant
using glutathione-sepharose as described by the manufacturer
(Amersham Biosciences). Twenty micrograms of each puriﬁed
fusion protein was mixed with Freund’s complete adjuvant and
used to immunize rats (Lewis, female 3 months old), followed by
multiple boosting.
Hybridoma production. Folowing immunization, blood samples
were collected to test serum reactivity against the SERA1-C
protein. From a positive mouse lymph node, cells were isolated
and fused to the mouse myeloma cell line X63Ag8.653. Super-
natants were screened by direct ELISA and single-cell clones
were isolated by limited dilution.
Puriﬁcation of antibodies. To collect polyclonal rat serum, immu-
nized animals were killed and heperanized blood was collected by
1732 A. Schmidt-Christensen, A. Sturm, S. Horstmann and V. T. Heussler
© 2008 The Authors
Journal compilation © 2008 Blackwell Publishing Ltd, Cellular Microbiology, 10, 1723–1734cardiac puncture. Serum was obtained after centrifugation. Mono-
clonal antibodies were isolated by applying the cell culture
supernatant to a Protein G-Sepharose column (Amersham Bio-
sciences). Total IgG was eluted from the column and dialysed
against PBS.
pL0032-SERA3 plasmid design and transfection
DNA was ampliﬁed by PCR from P. berghei blood stage parasite
gDNA template using the Phusion Taq DNA polymerase High
Fidelity enzyme (Finnzyme). Preparation of gDNAwas performed
using the Blood DNA Extract Kit (Qiagen). The P. berghei TAP
transfection plasmid pL0032, for homologous recombination into
the genome, was obtained from MR4. The 5′ UTR and the com-
plete PbSERA3 ORF targeting sequence were obtained by
ampliﬁcation of P. berghei gDNA using the primer set: SERA3-
TAP/for (5′-GCTCTAGATTTAACAATAAACTTTGCAAAATAGTG
AAT-3′) and SERA3-TAP/rev (5′-CATGCCATGGACATAACA
GAAGAGACATTTGTTTTTTCC-3′). The resulting fragment was
cloned into the NcoI/XbaI cloning sites of pL0032 in frame with
the TAP-tag coding sequence. The plasmid was linearized for
transfection using the unique restriction site XcmI. Schizont-
stage parasites were transfected with 5 mg of puriﬁed plasmid
DNA (Machery and Nagel Kit PC100), as previously described
(Janse et al., 2006).
Southern blot
For isolation of parasite gDNA, infected mice were exsan-
guinated at 3–5% parasitemia and gDNAwas isolated from whole
blood as described above. Manipulation of recombinant DNAand
analysis of nucleic acids by Southern blot hybridization were
carried out using a non-radioactive labelling kit according to
manufacturers protocol (Amersham Biosciences).
Comparison of wild-type versus transgenic SERA3-TAP
parasite development
For counting oocysts, midguts of WT or SERA3-TAP transgenic
P. berghei-infected A. stephensi mosquitoes were stained in
0.5% mercurochrome in 0.9% NaCl 10 days after a blood meal.
Monitoring parasitemia in mice: sporozoites were prepared
from salivary glands of A. stephensi mosquitoes 21 days after an
infectious blood meal. A total of 30 000 WT or SERA3-TAP trans-
genic P. berghei sporozoites were injected intravenously into
three mice for each parasite strain. Parasitemia was monitored
by blood smears.
FACS sorting of exoerythrocytic GFP-expressing
P. berghei parasites
HepG2 cells were seeded 24 h prior infection in 24-well plates.
GFP-expressing P. berghei sporozoites from ﬁve to 10 well-
infected mosquitoes were used to infect each of three wells. Fifty
hours post infection, cells were detached by Accutase treatment,
pooled in 10 ml media and subsequently FACS sorted. Sorted
infected cells were immediately lysed and used for Western blot
analysis as described above.
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Supplementary material
The following supplementary material is available for this article
online:
Fig. S1. Comparison of PbSERA1–5 and P. falciparum SERA5.
Multiple alignment of amino acid sequence of P. berghei SERAs
with PfSERA5. Gaps are introduced to maximize homology. Light
grey shading indicates similarities. Dark grey shadings indicate
identities. The PfSERA5 processing sites by PfSUB1 (Yeoh et al.,
2007) are indicated by black shading and white letters. Asterisks
label the putative catalytical triade of SERA proteases.
Fig. S2. The SERA3 5′ non-transcribed region induces late GFP
expression in transgenic liver stage parasites. The entire 5′ UTR
of PbSERA3 gene was cloned in front of GFP into the plasmid
pL0031. P. berghei parasites were transfected with resulting
plasmid construct. Transgenic parasites were passaged through
mosquitoes and corresponding sporozoites were used to infect
HepG2 cells. Live imaging was performed at indicated time
points. As a control, transgenic parasites expressing GFP under
the constitutive pbeef1aa promoter were used to infect HepG2
cells. Bar = 10 mM.
Fig. S3. Normal development of transgenic P. berghei express-
ing TAP-tagged SERA3.
A. Insect stage. Mosquitoes were infected with wild-type (WT) or
transgenic P. berghei parasites expressing TAP-tagged SERA3.
10 days post infection, midguts of 6 (for WT) and 8 (for transgenic
parasites) mosquitoes were disected and the midguts were
stained with mercurochrome before oocystes were counted. The
numbers of oocystes of all individual mosquitoes are depicted on
the graph. B. Mammalian stage. Sporozoites were prepared from
salivary glands of infected mosquitoes and intravenously injected
into mice. Blood stage parasitemia was followed for 10 days. The
course of parasitemia for all individual mice is shown.
Fig. S4. WB analysis of synchronized P. berghei blood stages.
A mixed P. berghei culture was synchronized as described pre-
viously (Janse et al., 2006). Saponin and NP40 lysates were
prepared and subjected to SDS-PAGE. Upon transfer to nitrocel-
lulose membranes, Western blot analysis using anti-PbSERA3-N
(A) and anti-TAP (B) antiserum was performed.
Fig. S5. SERA3 localization in P. berghei-infected HepG2 cells.
Infected cells were ﬁxed 48 hpi and stained with an anti-
SERA3-N antiserum (red) and with an anti-Exp1 antiserum
(green). DNA was stained with Dapi.
This material is available as part of the online article from:
http://www.blackwell-synergy.com/doi/abs/10.1111/
j.1462-5822.2008.01162.x
Please note: Blackwell Publishing is not responsible for the
content or functionality of any supplementary materials supplied
by the authors. Any queries (other than missing material) should
be directed to the corresponding author for the article.
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